This bill sets minimum Medicaid reimbursement rates for private duty nursing services provided to eligible patients in New York. It requires payments to be at least 80% of the standard CHAMPUS/TRICARE rate for the New York area, effective July 1, 2026. The Department of Health must publish a detailed private duty nursing rate schedule at least 30 days before the effective date and annually thereafter. This directly affects Medicaid-enrolled patients receiving private duty nursing care and the home care providers who deliver these services.
Relates to program eligibility for plans comparable to Medicare part D; provides for analysis of health plans by the department of health to determine whether such health plans meet or exceed the Medicare part D standard; requires the department of health, in consultation with the department of financial services, to notify prescription drug insurers of the provisions of this act.
Establishes a specialized health home program to serve certain individuals with physical disabilities who are Medicaid eligible adults eighteen years of age or older with a diagnosis of a neurological, muscular, or neuromuscular condition, and a mobility impairment; provides that a specialized health home shall be reimbursed on a fee-for-service basis and shall receive enhanced rates of payment; makes related provisions.
This bill amends New York's education law to explicitly permit dentists to administer human papillomavirus (HPV) vaccinations as part of their professional practice. It directly affects dentists by expanding their scope of practice to include HPV vaccine administration, which is currently typically provided by physicians or nurses. The key provision adds "the administration of vaccinations against the human papillomavirus (HPV)" to the legal definition of dental practice under Section 6601. This change would allow dentists to provide HPV vaccines during routine dental visits, potentially increasing access to the vaccine. The bill takes effect 180 days after enactment.
Includes Lyme disease and other tick-borne diseases as occupational diseases for purposes of workers' compensation; clarifies that disability includes disability caused by Lyme disease or other tick-borne diseases; requires insurance coverage of long term medical care for Lyme disease and other tick borne diseases.
Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities including the benefits and limitations of non-invasive prenatal testing, the difference between non-invasive prenatal testing and prenatal diagnostic testing, and current recommendations from the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG).
Enacts the "public university emergency contraception education act" requiring public universities to develop, produce and distribute informational materials related to emergency contraception.
This bill creates a certification process for organizations providing in-home substance use disorder treatment services in New York. It requires applicants (including out-of-state entities registered with the state) to meet specific clinical standards, including conducting screenings for overdose risk, mental health conditions, and suicide risk. Certified providers must implement safety plans, medication-assisted treatment, naloxone access, and regular recovery planning. The law aims to standardize and expand access to in-home treatment while ensuring providers meet defined safety and clinical requirements.
Establishes an intensive addiction and medical services integrated services pilot program to support two three-year demonstration programs that provide intensive addiction and medical services integrated services to individuals who have significant addiction and medical issues.
Provides that the prescribing, dispensing, or receipt of mifepristone or any drug used for medication abortion shall not be considered a criminal conversion act under certain circumstances; provides that mifepristone or any drug used for medication abortion shall not be deemed to be adulterated or misbranded under certain circumstances.
